mass spectrometric immunoassay
Newborn Exome Sequencing Shows Potential to Help Find Inborn Errors of Metabolism
Exome sequencing had lower sensitivity and specificity for finding inborn errors of metabolism than conventional screening, but appeared to refine mass spec-based results.
Danaher Q4 Revenues Climb 6 Percent
Life Sciences revenues grew 7 percent year over year to $1.92 billion, while Diagnostics revenues were up rose also 7 percent to $1.80 billion.
Fluidigm Sues IonPath for Patent Infringement, Interference
The South San Francisco, California cellular analysis firm alleges IonPath has infringed two patents and has been intereferening in its contracts.
The new partnership will support the analysis of glycans in 30,000 human samples by the end of 2021.
Danaher Q4 Revenues Up 5 Percent
The firm's Life Sciences segment grew 10 percent year over year during the quarter while its Diagnostics segment was up 4 percent.